Physician
Premier Eye Care of Eastern Idaho
Premier Eye Care of Eastern Idaho was paid $1.44M by Medicaid between Jan 2018 and Dec 2024, across 16 billing codes. Its largest line is J2778, Injection, ranibizumab, 0.1 mg — 70% of everything it billed.
33Billing provider infoPREMIER EYE CARE OF EASTERN IDAHO
IDAHO FALLS, ID 83404
IDAHO FALLS, ID 83404
33aNPI1790052603assigned 11/20/2011
33bProvider typeOphthalmology Physician
28Total paid$1.44M
24GClaims10,862
24DCodes billed16
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ophthalmology Physician providers in Idaho
Rank by total paid#2 of 22
Median peer was paid$43K
This provider vs. median34×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 729 | $18K | |
| 2019 | 811 | $24K | |
| 2020 | 1,015 | $49K | |
| 2021 | 1,577 | $90K | |
| 2022 | 2,153 | $397K | |
| 2023 | 2,403 | $519K | |
| 2024incomplete | 2,174 | $338K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg | 70% | 1,245 | 1,152 | $1.00M |
| 67028 | Intravitreal injection of a pharmacologic agent | 13% | 3,212 | 2,878 | $180K |
| 92134 | 4.9% | 3,087 | 2,681 | $70K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 3.9% | 1,076 | 1,013 | $56K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.8% | 683 | 635 | $40K |
| J9035 | Injection, bevacizumab, 10 mg | 1.4% | 291 | 279 | $20K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.2% | 243 | 241 | $17K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 247 | 231 | $14K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | <1% | 14 | 14 | $12K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 102 | 101 | $11K |
| 92250 | <1% | 278 | 263 | $7K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 246 | 216 | $4K |
4 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTRAYNOR, MATTHEW (OWNER)